| Combination of | |
|---|---|
| Beclometasone dipropionate | Glucocorticoid |
| Formoterol fumarate dihydrate | Long-acting β2 agonist |
| Glycopyrronium bromide | Antimuscarinic |
| Clinical data | |
| Trade names | Trimbow, others |
| AHFS/Drugs.com | UK Drug Information |
| Routes of administration | Inhalation |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
Beclometasone/formoterol/glycopyrronium, sold under the brand name Trimbow among others, is an inhalable fixed-dose combination medication for the treatment of chronic obstructive pulmonary disease (COPD) and asthma. It contains beclometasone dipropionate, formoterol fumarate dihydrate, and glycopyrronium bromide.[3][4]
Side effects include oral candidiasis (a fungal infection of the mouth caused by a yeast called Candida), muscle spasms and dry mouth.[3][4]
Beclometasone/formoterol/glycopyrronium was approved for use in the European Union in July 2017, and in April 2018.[3][4][5]
- ^ "Trimbow ARTG ID 314166". Therapeutic Goods Administration (TGA). Retrieved 21 July 2020.
- ^ "Trimbow 87 micrograms/5 micrograms/9 micrograms pressurised inhalation, solution - Summary of Product Characteristics (SmPC)". (emc). 8 February 2019. Retrieved 5 March 2020.
- ^ a b c "Trimbow EPAR". European Medicines Agency (EMA). 5 March 2020. Retrieved 5 March 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ a b c "Trydonis EPAR". European Medicines Agency (EMA). 21 July 2020. Retrieved 21 July 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ "Riarify EPAR". European Medicines Agency (EMA). 26 April 2018. Retrieved 21 July 2020.